A 2019 literature review summarizes the finding on using THC and CBD on patients with dementia. Researchers found that Dronabinol and THC were associated with significant improvements in a range of psychiatric scores. Interestingly, cannabis products showed the most promising results in patients whose symptoms were previously unmanageable or resistant to other treatments.
Human study finds that, when taken with opioids, dronabinol (THC) may increase impairment and decrease, or not affect, pain relief. Researchers conclude that THC might NOT protect the body from the adverse effects of opioids. However, the study examined only 10 participants, and such a small sample size should give pause to the validity and applicability of the findings.
In a crossover trial of 39 patients with Alzheimer’s disease, treatment with nabilone (a synthetic THC analog) was associated with significant improvement in agitation and, remarkably, cognition. Further studies should examine the effects of both THC and CBD in patients with Alzheimer’s disease because anxiety is common in dementia and may exacerbate agitation.
Study provides rigorous data to support clinical evaluation of THC as a low-toxic therapy option in acute leukemia patients. In related work, full-spectrum, natural derivatives of cannabis may work more effectively than their pharmaceutical counterparts.
Pharmaceutical Cannabis Derivatives Help Discover their Receptors and Functions for Autoimmune Illnesses
A recent study conducted by Michigan State University exposed the potential for cannabinoid receptor 2 (CB2) to target the treatment of inflammatory conditions. Elevated levels of plasmacytoid dendritic cells (pCD, a type of cell in the immune system) contribute to chronic inflammation in autoimmune diseases, such as Rheumatoid Arthritis. Researchers found that synthetic CB2 agonists reported comparable benefits to THC, but minimized the cerebral effects as the psychotropic activity is mediated by cannabinoid receptor 1 (CB1). This evidence demonstrates the potential benefits of CB2-targeted treatment for inflammatory conditions. Unfortunately, there are serious concerns about the misuse of some synthetic cannabinoids, so there is still a missing bridge, in products and public education, between these research products and potential therapeutic pharmaceuticals, down the road.
The use of synthetic cannabinoids in English prisons is currently considered a “law, order and control” problem, with associated regulation and penalties. There is a clear and problematic disconnect between prison administrators and users. Resources for education, training and work opportunities are missing.